Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2015

01-06-2015 | Research Article

Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer

Authors: Dan-dan Yin, Zhi-jun Liu, Erbao Zhang, Rong Kong, Zhi-hong Zhang, Ren-hua Guo

Published in: Tumor Biology | Issue 6/2015

Login to get access

Abstract

Colorectal cancer (CRC) remains an important public health problem in the world. Long noncoding RNA (lncRNA) is an RNA molecular that is longer than 200 nucleotides and cannot be translated into a protein. Recent studies have shown that lncRNAs play important roles in carcinogenesis and cancer metastasis. The aim of this study was to evaluate the expression and biological role of lncRNA maternally expressed gene 3 (MEG3) in colorectal cancer. Quantitative real-time-PCR (qRT-PCR) was performed to investigate the expression of MEG3 in tumor tissues and corresponding nontumor colorectal tissues from 62 patients. The lower expression of MEG3 was remarkably correlated with low histological grade, deep tumor invasion, and advanced tumor node metastasis (TNM) stage. Multivariate analyses revealed that MEG3 expression served as an independent predictor for overall survival. Further experiments revealed that overexpressed MEG3 significantly inhibited CRC cell proliferation both in vitro and in vivo. In conclusion, our study demonstrated that MEG3 is involved in the development and progression of colorectal cancer by regulating cell proliferation and shows that MEG3 may be a potential diagnostic and prognostic target in patients with colorectal cancer.
Literature
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.CrossRefPubMed
2.
Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544–73.CrossRefPubMedPubMedCentral
3.
4.
Mattick JS, Taft RJ, Faulkner GJ. A global view of genomic information—moving beyond the gene and the master regulator. Trends Genet. 2010;26:21–8.CrossRefPubMed
5.
Chen G, Wang Z, Wang D, Qiu C, Liu M, Chen X, et al. LncRNADisease: a database for long-non-coding RNA-associated diseases. Nucleic Acids Res. 2013;41:D983–986.CrossRefPubMed
6.
7.
Benetatos L, Vartholomatos G, Hatzimichael E. Meg3 imprinted gene contribution in tumorigenesis. Int J Cancer. 2011;129:773–9.CrossRefPubMed
8.
9.
Schuster-Gossler K, Bilinski P, Sado T, Ferguson-Smith A, Gossler A. The mouse gtl2 gene is differentially expressed during embryonic development, encodes multiple alternatively spliced transcripts, and may act as an RNA. Dev Dyn. 1998;212:214–28.CrossRefPubMed
10.
da Rocha ST, Edwards CA, Ito M, Ogata T, Ferguson-Smith AC. Genomic imprinting at the mammalian dlk1-dio3 domain. Trends Genet. 2008;24:306–16.CrossRefPubMed
11.
Wang P, Ren Z, Sun P. Overexpression of the long non-coding RNA meg3 impairs in vitro glioma cell proliferation. J Cell Biochem. 2012;113:1868–74.CrossRefPubMed
12.
Anwar SL, Krech T, Hasemeier B, Schipper E, Schweitzer N, Vogel A, et al. Loss of imprinting and allelic switching at the dlk1-meg3 locus in human hepatocellular carcinoma. PLoS One. 2012;7:e49462.CrossRefPubMedPubMedCentral
13.
Ying L, Huang Y, Chen H, Wang Y, Xia L, Chen Y, et al. Downregulated meg3 activates autophagy and increases cell proliferation in bladder cancer. Mol Biosyst. 2013;9:407–11.CrossRefPubMed
14.
Balik V, Srovnal J, Sulla I, Kalita O, Foltanova T, Vaverka M, et al. Meg3: a novel long noncoding potentially tumour-suppressing RNA in meningiomas. J Neurooncol. 2013;112:1–8.CrossRefPubMed
15.
Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR, et al. A pituitary-derived meg3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab. 2003;88:5119–26.CrossRefPubMed
16.
Zhang X, Rice K, Wang Y, Chen W, Zhong Y, Nakayama Y, et al. Maternally expressed gene 3 (meg3) noncoding ribonucleic acid: isoform structure, expression, and functions. Endocrinology. 2010;151:939–47.CrossRefPubMed
17.
Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, Gejman R, et al. Activation of p53 by meg3 non-coding RNA. J Biol Chem. 2007;282:24731–42.CrossRefPubMed
18.
Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA hotair reprograms chromatin state to promote cancer metastasis. Nature. 2010;464:1071–6.CrossRefPubMedPubMedCentral
19.
Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M, et al. Long non-coding RNA anril is required for the prc2 recruitment to and silencing of p15(ink4b) tumor suppressor gene. Oncogene. 2011;30:1956–62.CrossRefPubMed
20.
Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F, et al. Tgf-beta-induced upregulation of malat1 promotes bladder cancer metastasis by associating with suz12. Clin Cancer Res. 2014;20:1531–41.CrossRefPubMed
21.
Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, et al. Pcat-1, a long noncoding RNA, regulates brca2 and controls homologous recombination in cancer. Cancer Res. 2014;74:1651–60.CrossRefPubMedPubMedCentral
22.
Geng YJ, Xie SL, Li Q, Ma J, Wang GY. Large intervening non-coding RNA hotair is associated with hepatocellular carcinoma progression. J Int Med Res. 2011;39:2119–28.CrossRefPubMed
23.
Niinuma T, Suzuki H, Nojima M, Nosho K, Yamamoto H, Takamaru H, et al. Upregulation of mir-196a and hotair drive malignant character in gastrointestinal stromal tumors. Cancer Res. 2012;72:1126–36.CrossRefPubMed
24.
Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T, et al. Long noncoding RNA hotair regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res. 2011;71:6320–6.CrossRefPubMed
25.
Zhang EB, Kong R, Yin DD, You LH, Sun M, Han L, et al. Long noncoding RNA anril indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of mir-99a/mir-449a. Oncotarget. 2014;5:2276–92.CrossRefPubMedPubMedCentral
26.
Yin D, He X, Zhang E, Kong R, De W, Zhang Z. Long noncoding RNA gas5 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer. Med Oncol. 2014;31:253.CrossRefPubMed
27.
Khaitan D, Dinger ME, Mazar J, Crawford J, Smith MA, Mattick JS, et al. The melanoma-upregulated long noncoding RNA spry4-it1 modulates apoptosis and invasion. Cancer Res. 2011;71:3852–62.CrossRefPubMed
28.
29.
Ji Q, Zhang L, Liu X, Zhou L, Wang W, Han Z, Sui H, Tang Y, Wang Y, Liu N, Ren J, Hou F, Li Q. Long non-coding rna malat1 promotes tumour growth and metastasis in colorectal cancer through binding to sfpq and releasing oncogene ptbp2 from sfpq/ptbp2 complex. Br J Cancer. 2014.
30.
Han Y, Yang YN, Yuan HH, Zhang TT, Sui H, Wei XL, et al. Uca1, a long non-coding RNA up-regulated in colorectal cancer influences cell proliferation, apoptosis and cell cycle distribution. Pathology. 2014;46:396–401.CrossRefPubMed
31.
Guo Q, Zhao Y, Chen J, Hu J, Wang S, Zhang D, et al. Braf-activated long non-coding RNA contributes to colorectal cancer migration by inducing epithelial-mesenchymal transition. Oncol Lett. 2014;8:869–75.PubMedPubMedCentral
Metadata
Title
Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer
Authors
Dan-dan Yin
Zhi-jun Liu
Erbao Zhang
Rong Kong
Zhi-hong Zhang
Ren-hua Guo
Publication date
01-06-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3139-2

Other articles of this Issue 6/2015

Tumor Biology 6/2015 Go to the issue

Research Article

MicroRNA-15a induces cell apoptosis and inhibits metastasis by targeting BCL2L2 in non-small cell lung cancer

Research Article

The impact of positive nodal chain ratio on individualized multimodality therapy in non-small-cell lung cancer

Research Article

Combined Runx2 and Snail overexpression is associated with a poor prognosis in breast cancer

Research Article

Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity

Research Article

Divergent expression patterns of SATB1 mRNA and SATB1 protein in colorectal cancer and normal tissues

Research Article

Overexpression of CUGBP1 is associated with the progression of non-small cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits